Literature DB >> 27997854

The emerging metabolic view of Clostridium difficile pathogenesis.

Andrew J Hryckowian1, Kali M Pruss1, Justin L Sonnenburg2.   

Abstract

It is widely accepted that Clostridium difficile exploits dysbiosis and leverages inflammation to thrive in the gut environment, where it can asymptomatically colonize humans or cause a toxin-mediated disease ranging in severity from frequent watery diarrhea to pseudomembranous colitis or toxic megacolon. Here, we synthesize recent findings from the gut microbiota and enteric pathogenesis fields to inform the next steps toward a better understanding of C. difficile infection (CDI). In this review, we present a model in which the lifestyle of C. difficile is dictated by the metabolic state of the distal gut ecosystem. Contributions by C. difficile (specifically the production and action of the large glycosylating toxins TcdA and TcdB), the microbiota, and the host dictate whether the gut environment is supportive to the pathogen. Mechanistic, metabolic pathway-focused approaches encompassing the roles of all of these players are helping to elucidate the molecular ecology of the distal gut underlying a diseased or healthy ecosystem. A new generation of therapeutic strategies that are more targeted (and palatable) than fecal microbiota transplants or broad-spectrum antibiotics will be fueled by insight into the interspecies (host-microbe and microbe-microbe) interactions that differentiate healthy from pathogen-infested microbiotas.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27997854      PMCID: PMC5474191          DOI: 10.1016/j.mib.2016.11.006

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  48 in total

1.  Glycan foraging in vivo by an intestine-adapted bacterial symbiont.

Authors:  Justin L Sonnenburg; Jian Xu; Douglas D Leip; Chien-Huan Chen; Benjamin P Westover; Jeremy Weatherford; Jeremy D Buhler; Jeffrey I Gordon
Journal:  Science       Date:  2005-03-25       Impact factor: 47.728

2.  Intestinal inflammation allows Salmonella to use ethanolamine to compete with the microbiota.

Authors:  Parameth Thiennimitr; Sebastian E Winter; Maria G Winter; Mariana N Xavier; Vladimir Tolstikov; Douglas L Huseby; Torsten Sterzenbach; Renée M Tsolis; John R Roth; Andreas J Bäumler
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

3.  Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection.

Authors:  Susana Fuentes; Els van Nood; Sebastian Tims; Ineke Heikamp-de Jong; Cajo J F ter Braak; Josbert J Keller; Erwin G Zoetendal; Willem M de Vos
Journal:  ISME J       Date:  2014-02-27       Impact factor: 10.302

4.  Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.

Authors:  Daniel E Freedberg; Hojjat Salmasian; Carol Friedman; Julian A Abrams
Journal:  Am J Gastroenterol       Date:  2013-09-24       Impact factor: 10.864

5.  Antibiotic-Induced Alterations of the Murine Gut Microbiota and Subsequent Effects on Colonization Resistance against Clostridium difficile.

Authors:  Alyxandria M Schubert; Hamide Sinani; Patrick D Schloss
Journal:  mBio       Date:  2015-07-14       Impact factor: 7.867

6.  Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

Authors:  Charlie G Buffie; Vanni Bucci; Richard R Stein; Peter T McKenney; Lilan Ling; Asia Gobourne; Daniel No; Hui Liu; Melissa Kinnebrew; Agnes Viale; Eric Littmann; Marcel R M van den Brink; Robert R Jenq; Ying Taur; Chris Sander; Justin R Cross; Nora C Toussaint; Joao B Xavier; Eric G Pamer
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

7.  Host-mediated sugar oxidation promotes post-antibiotic pathogen expansion.

Authors:  Franziska Faber; Lisa Tran; Mariana X Byndloss; Christopher A Lopez; Eric M Velazquez; Tobias Kerrinnes; Sean-Paul Nuccio; Tamding Wangdi; Oliver Fiehn; Renée M Tsolis; Andreas J Bäumler
Journal:  Nature       Date:  2016-06-15       Impact factor: 49.962

8.  Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut.

Authors:  Elaine O Petrof; Gregory B Gloor; Stephen J Vanner; Scott J Weese; David Carter; Michelle C Daigneault; Eric M Brown; Kathleen Schroeter; Emma Allen-Vercoe
Journal:  Microbiome       Date:  2013-01-09       Impact factor: 14.650

9.  Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection.

Authors:  Yang Song; Shashank Garg; Mohit Girotra; Cynthia Maddox; Erik C von Rosenvinge; Anand Dutta; Sudhir Dutta; W Florian Fricke
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

Review 10.  Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications.

Authors:  Luis Furuya-Kanamori; John Marquess; Laith Yakob; Thomas V Riley; David L Paterson; Niki F Foster; Charlotte A Huber; Archie C A Clements
Journal:  BMC Infect Dis       Date:  2015-11-14       Impact factor: 3.090

View more
  20 in total

1.  Misoprostol protects mice against severe Clostridium difficile infection and promotes recovery of the gut microbiota after antibiotic perturbation.

Authors:  Joseph P Zackular; Leslie Kirk; Bruno C Trindade; Eric P Skaar; David M Aronoff
Journal:  Anaerobe       Date:  2019-06-17       Impact factor: 3.331

2.  Clostridioides difficile-Associated Antibiotics Alter Human Mucosal Barrier Functions by Microbiome-Independent Mechanisms.

Authors:  Jemila C Kester; Douglas K Brubaker; Jason Velazquez; Charles Wright; Douglas A Lauffenburger; Linda G Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection.

Authors:  Brandon J Webb; Aruna Subramanian; Bert Lopansri; Bruce Goodman; Peter Bjorn Jones; Jeffrey Ferraro; Edward Stenehjem; Samuel M Brown
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  Flexible Cobamide Metabolism in Clostridioides (Clostridium) difficile 630 Δerm.

Authors:  Amanda N Shelton; Xun Lyu; Michiko E Taga
Journal:  J Bacteriol       Date:  2020-01-02       Impact factor: 3.490

Review 5.  Computational approaches to understanding Clostridioides difficile metabolism and virulence.

Authors:  Matthew L Jenior; Jason A Papin
Journal:  Curr Opin Microbiol       Date:  2021-11-25       Impact factor: 7.934

6.  Diverse Energy-Conserving Pathways in Clostridium difficile: Growth in the Absence of Amino Acid Stickland Acceptors and the Role of the Wood-Ljungdahl Pathway.

Authors:  Simonida Gencic; David A Grahame
Journal:  J Bacteriol       Date:  2020-09-23       Impact factor: 3.490

7.  Mucin-Degrading Microbes Release Monosaccharides That Chemoattract Clostridioides difficile and Facilitate Colonization of the Human Intestinal Mucus Layer.

Authors:  Melinda A Engevik; Amy C Engevik; Kristen A Engevik; Jennifer M Auchtung; Alexandra L Chang-Graham; Wenly Ruan; Ruth Ann Luna; Joseph M Hyser; Jennifer K Spinler; James Versalovic
Journal:  ACS Infect Dis       Date:  2020-11-11       Impact factor: 5.084

Review 8.  Role of Proline in Pathogen and Host Interactions.

Authors:  Shelbi L Christgen; Donald F Becker
Journal:  Antioxid Redox Signal       Date:  2018-02-02       Impact factor: 8.401

9.  C. difficile exploits a host metabolite produced during toxin-mediated disease.

Authors:  Kali M Pruss; Justin L Sonnenburg
Journal:  Nature       Date:  2021-04-28       Impact factor: 69.504

10.  Comparative genome and phenotypic analysis of three Clostridioides difficile strains isolated from a single patient provide insight into multiple infection of C. difficile.

Authors:  Uwe Groß; Elzbieta Brzuszkiewicz; Katrin Gunka; Jessica Starke; Thomas Riedel; Boyke Bunk; Cathrin Spröer; Daniela Wetzel; Anja Poehlein; Cynthia Chibani; Wolfgang Bohne; Jörg Overmann; Ortrud Zimmermann; Rolf Daniel; Heiko Liesegang
Journal:  BMC Genomics       Date:  2018-01-02       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.